Table 1.

Clinical and biologic characteristics of patients in the whole population according to the propranolol treatment or not

VariablesPatients not treated by propranolol (N = 241)Patients treated by propranolol (N = 50)P
Age, y55.7 (44.59–67.14)63.5 (52.9–69.07)0.010a
BMI, kg/m224.9 (23.03–27.97)23.8 (21.86–26.83)0.095a
Male139 (57.7%)23 (46%)0.13
Mixed etiology91 (38.7%)15 (30%)0.24
Diabetes70 (31.3%)17 (35.4%)0.57
Serum AFP, ng/mL8 (5–12)7 (5–11)0.74a
Prothrombin activity (%)80 (69–91)77 (61–90)0.31a
Serum albumin, g/L41.03 ± 5.5840.49 ± 5.070.53
Serum bilirubin, μmol/L13 (9–20)15 (10–24)0.28a
Platelet count (×109/L)124 (90–170.5)91.5 (64–130)0.0005a
ALT (ULN)2.2 (1.5–3.8)2.05 (1.5–3.1)0.75a
AST (ULN)1.8 (1.3–2.8)2 (1.5–3)0.43a
Alkaline phosphatase (ULN)1 (1–1.4)1.1 (1–1.6)0.09a
Child–Pugh B12 (5%)5 (10%)0.18a
GGT (ULN)2 (1.2–3)1.9 (1–3.5)0.57a

NOTE: Mixed etiology for past or ongoing daily alcohol intake >30 g/d AST, ALT, GGT.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltransferase; ULN, upper normal limit range.

a For quantitative variables.